Novo Nordisk AS Newswire (Page 8)

Novo Nordisk AS Newswire (Page 8)

Comprehensive Real-Time News Feed for Novo Nordisk AS. (Page 8)

Results 141 - 160 of 27,589 in Novo Nordisk AS

  1. 3 Beaten-Up Big Pharma Stocks: Are They Bargains Now?Read the original story w/Photo

    Oct 7, 2016 | The Motley Fool

    Healthcare stocks in general have fared all right over the past 12 months, but there have also been quite a few losers among them. Big pharma stocks in particular have experienced mixed results, and three major drugmakers have performed especially poorly: Novartis The picture hasn't been pretty for any of these companies over the past year: Shares of each have fallen by double-digit percentages.

    Comment?

  2. Novo Nordisk Is Being IgnoredRead the original story w/Photo

    Oct 6, 2016 | GuruFocus.com

    Novo Nordisk , the $106.9 billion pharmaceutical giant, delivered its first fiscal 2016 earnings on Aug. 5 with a sales and profit growth of 5% to 54.67 billion Danish kroner and 7% to 19.4 billion kroner . Despite its year-on-year growth, Novo Nordisk shares closed down 9.66% that day while the broader Standard & Poor's 500 closed up 0.86%.

    Comment?

  3. 16th annual AMH diabetes fair scheduled for Nov. 5Read the original story w/Photo

    Oct 6, 2016 | RiverBender.com

    ALTON, IL A popular television chef will share healthy recipes as part of Alton Memorial Hospital's 16th annual Diabetes Fair on Saturday, Nov. 5. This educational and fun event will be held from 9 a.m. to noon in the hospital's Beeby Wing lobby and cafeteria. The Diabetes Fair is part of National Diabetes Month.

    Comment?

  4. Denmark's DSV eyes more big acquisitions in fragmented freight marketRead the original story w/Photo

    Oct 4, 2016 | Reuters

    COPENHAGEN, Oct 4 Denmark's DSV, which became the world's fifth largest freight transportation company by buying up competitors, is considering more large acquisitions to expand in a fragmented market despite weak growth in global trade. The company's simple corporate structure and success in turning around loss-making firms has helped to boost its shares by 25 percent this year as it integrates its $1.35 billion acquisition of loss-making, California-based UTi in January.

    Comment?

  5. Should We Screen for Type 2 Diabetes? Grand Rounds Discussion From...Read the original story

    Oct 3, 2016 | Annals of Internal Medicine

    Disclosures: Dr. Rind reports personal fees from UpToDate outside the submitted work. Dr. Abrahamson has served on Advisory Boards for Novo Nordisk.

    Comment?

  6. Reading Roundup: Top Blog Posts from September 2016Read the original story w/Photo

    Oct 3, 2016 | Pharmaceutical Engineering

    It's time for another edition of the Reading Roundup featuring the top blog posts from September 2016. Grab your favorite cup of coffee, kick back and catch-up on what the pharmaceutical industry was reading in May. There have been situations where people struggled to separate integrity and quality.

    Comment?

  7. Novo Nordisk (NVO) Stock Drops, Explores Inventing New Forms of InsulinRead the original story w/Photo

    Oct 3, 2016 | TheStreet.com

    ... rating may differ from Jim Cramer's view or that of this articles's author. The Street Ratings team rates Novo Nordisk as a Buy with a ratings score of B. The company's strengths can be seen in multiple areas, such as its growth in earnings per ...

    Comment?

  8. Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own sharesRead the original story w/Photo

    Oct 3, 2016 | GlobeNewswire

    BagsvA rd, Denmark, 3 October 2016 - In continuation of the company's announcements dated 3 February 2016 and 5 August 2016 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S and its wholly-owned affiliates on 30 September 2016 owned 29,476,648 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 5,895,330 or 1.2% of the total share capital.

    Comment?

  9. Novo Nordisk A/S (NVO) - Analysts' Recent Ratings ChangesRead the original story w/Photo

    Oct 3, 2016 | AmericanBankingNews.com

    A number of firms have modified their ratings and price targets on shares of Novo Nordisk A/S recently: 9/23/2016 - Novo Nordisk A/S is now covered by analysts at Piper Jaffray Cos.. They set a "neutral" rating on the stock.

    Comment?

  10. Novo Nordisk: manufacturing jobs safe amid cost-cutting measuresRead the original story w/Photo

    Oct 3, 2016 | In-PharmaTechnologist.com

    The loss of 1,000 jobs is the latest cost-cutting initiative from Novo Nordisk but no manufacturing positions are at risk, the firm says. Last week, the Danish drugmaker announced it was axing approximately 1,000 jobs, or 2.4% of its 42,300 global workforce.

    Comment?

  11. Today's Top Gainers in the Market Novo Nordisk A/S (NYSE:NVO) from HealthcareRead the original story w/Photo

    Oct 3, 2016 | The Daily Leicester

    Today's top gainers include the company Novo Nordisk A/S which is in the industry Drug Manufacturers - Other , gaining -0.50% today. In the last week its performance is -7.33%, and -22.63% for the past quarter.

    Comment?

  12. Novo Nordisk Bets on Riskier Insulin ResearchRead the original story

    Oct 2, 2016 | WRKO-AM Brighton

    Danish pharmaceutical company Novo Nordisk is moving into the complex and more expensive business of inventing new forms of insulin, which would bring it closer to the riskier drug-discovery activities of the wider pharmaceutical industry.

    Comment?

  13. Boston Advisors LLC Lowers Position in Novo Nordisk A/SRead the original story w/Photo

    Oct 2, 2016 | Daily Political

    Boston Advisors LLC decreased its position in Novo Nordisk A/S by 8.2% during the second quarter, Holdings Channel reports. The fund owned 23,710 shares of the company's stock after selling 2,110 shares during the period.

    Comment?

  14. Emerging Trends in the Aged Care MarketRead the original story w/Photo

    Sep 30, 2016 | PR-inside.com

    Most of us want to remain independent and stay in control, but due to growing age our ability starts to decline. Hence, the concept of aged care is introduced, for an easy and better living with proper nursing facility for the higher age group.

    Comment?

  15. Analysis: Diabetes drug price war likely to claim more casualtiesRead the original story w/Photo

    Sep 30, 2016 | Indianapolis Business News

    Through no fault of their own, 1,000 people just became victims of a drug-price war mostly taking place on another continent.

    Comment?

  16. Novo Nordisk: Long-Term Growth at a Good PriceRead the original story w/Photo

    Sep 30, 2016 | TheStreet.com

    I used Danish pharmaceutical company Novo Nordisk as an example recently when comparing "buy-and-hold" strategies to "trading." At that time I had no position in NVO.

    Comment?

  17. vTv Therapeutics Inc. (VTVT) Now Covered by HC WainwrightRead the original story w/Photo

    Sep 30, 2016 | Daily Political

    The brokerage issued a buy rating and a $13.00 target price on the stock. "We are more enthusiastic about the two diabetes drugs that should be ripe for partnering upon success in Phase 2. TTP399 completed a successful Phase 2b in August and TTP273 should have Phase 2b data in December, the nearest term catalyst," analyst Corey Davis wrote in a note.Related Link: vTV Therapeutics Completes Enrollment For PHase 2 TTP273 TrialOn the other hand, although Azeliragon could be "one of the next wave of promising Alzheimer's drugs," the analyst is not expecting the stock to move near term on this drug given the history and lack of data until 2018.The upcoming catalysts include TTP273 Phase 2 data in diabetes and publication of Phase 2 results from TTP399 in diabetes, both expected in late 2016.

    Comment?

  18. Novo Nordisk Plans to Cut 1,000 Jobs Amid Diabetes Price WarRead the original story

    Sep 29, 2016 | The Washington Post

    Novo Nordisk A/S plans to trim about 1,000 jobs, or 2 percent of the workforce at the world's biggest maker of insulin, to cut costs as it faces increasing competition and resistance to high prices for diabetes products in the U.S. Most cuts will be in research and development units and staff functions at its headquarters, as well as in the global commercial organization, the Bagsvaerd, Denmark-based company said in a statement on Thursday. The headcount reduction is part of a broader effort to pare expenses.

    Comment?

  19. Garrison Financial Corp Sells 175 Shares of Novo Nordisk A/SRead the original story w/Photo

    Sep 29, 2016 | Daily Political

    Garrison Financial Corp reduced its position in shares of Novo Nordisk A/S by 1.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,950 shares of the company's stock after selling 175 shares during the period.

    Comment?

  20. The Diabetes Price War Claims CasualtiesRead the original story w/Photo

    Sep 29, 2016 | Bloomberg

    Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

    Comment?